NRAS and non-small cell lung carcinoma: NRAS mutations (and novel E63K) were described in vitro together with a gain of a copy of wild-type NRAS or wild-type KRAS in NSCLC EGFR–mutated cell lines resistant to gefitinib, afatinib or osimertinib [127].